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Abstract
Background: Temporomandibular joint dysfunction are often accompanied by symptoms of headache such as
tension-type headache which is the most frequent spontaneous primary headache. Masseter muscle pain is
commonly reported in this group. The purpose of the study was to assess the efficiency of intramuscular botulinum
toxin type A injections for treating masseter muscle pain in patients with temporomandibular joint dysfunction and
tension-type headache.
Methods: This prospective outcome study consisted of 42 subjects of both genders aged 19–48 years diagnosed
with masseter muscle pain related to temporomandibular joint dysfunction and tension-type headache. The
subjects were treated by the intramuscular injection of 21 U (mice units) of botulinum toxin type A (Botox,
Allergan) in the area of the greatest cross-section surface of both masseter bellies. Pain intensity was evaluated
using visual analogue scale (VAS) and verbal numerical rating scale (VNRS) 1 week before the treatment and
24 weeks after the treatment. The obtained data were analyzed using the Wilcoxon matched pairs test (p ≤ 0,005).
Results: The results of this study showed a decrease in the number of referred pain episodes including a decrease
in pain in the temporal region bilaterally, a reduction of analgesic drugs intake as well as a decrease in reported
values of VAS and VNRS after injections (p = 0,000).
Conclusions: The intramuscular botulinum toxin type A injections have been an efficient method of treatment for
masseter muscle pain in patients with temporomandibular joint dysfunction and tension-type headache.
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Background
Symptoms characteristic for temporomandibular joint
dysfunction (TMJD) such as masticatory muscles pain,
temporomandibular joint pain, derangements of the
condyle-disc complex and deviations of mandible move-
ments are often accompanied by symptoms that are not
directly related to the functioning of the temporoman-
dibular joint [1–8]. Such signs include otologic symptoms
(ear pain, tinnitus, vertigo), neurovascular headaches and
tension-type headaches (TTH) [9–13]. TTH are the most
frequent spontaneous primary headaches. They are ob-
served more frequently in women, and occurred in all age
groups. It should be emphasized that in most cases the
TTH affect middle-aged patients. This kind of headache
was also observed in approximately 5–7 % of students
aged 5–15 years. The American Dental Association stated
that more than 15 % of American adults suffer from
chronic headache pain [11–16].
Diagnostics of TTHs is based on the data collected in
a screening history consisted short questions which let
to analyze the background of the pain and the factors
responsible for pain origin. Specialized neuroimaging
modalities (magnetic resonance, angiography, positron
emission tomography) are used less frequently. The
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results of additional tests provide to exclude other
causes of the TTH, especially migraine headache, aseptic
meningitis, neuroborreliosis or pseudotumor cerebri [11,
17–18]. The following disorders should also be taken
into consideration in differential diagnosis: hemicrania
continua, spinal cord injury, central nervous system disor-
ders and depression. Sinus pain, medication-induced
headache and intracranial hypertension may also be
important. TTH may be caused by psychoemotional
factors, chronic stress, fatigue, sleep disorders and se-
vere dehydration [17–22].
Bilateral, constant, dull ache of mild to moderate in-
tensity without preexisting aura, vomiting, nausea is
characteristic of TTH. Although TTH are not as widely
recognized as migraine headaches, they constitute an
important and frequent clinical problem, as they exert
negative impact on the patients’ quality of life. Tension-
type headache is affecting the temporal and occipital re-
gion. The patient may also report the feeling of squeez-
ing within the head. In the beginning the headache is
not intensive. Later it could intensify and gain the same
level of pain as the migraine headache. Moreover, the
frequency at which TTH occurs is important for diagno-
sis: it lasts at least 30 min daily, occurs on 15 days in a
month, affects the patient for more than 3 months, and
is detected in all age groups, but it affects middle-aged
people most frequently. TTH are frequently accompan-
ied by sleep disorders, chronic fatigue syndrome,
noise hypersensitivity and appetite loss [13, 15, 22].
Risk factors include: gender (women are affected
more frequently), hormone changes, emotional stress,
depression, anxiety and genetic factors. Moreover,
TTH could be a result of head and neck injury, brux-
ism, and psychoactive and analgesic drug intake. Ac-
cording to the latest edition of the International
Classification of Headache Disorders (ICHD-3 beta)
prepared by the International Headache Society, TTH can
be classified into: infrequent tension-type headaches, fre-
quent tension-type headaches, chronic tension-type head-
aches, and probable tension-type headaches. Tension-type
headaches accompany temporomandibular joint dysfunc-
tion with varying frequency because head and neck mus-
cles remain in close anatomical and physiological
relationship [22–26].
The aim of this prospective outcome study was to as-
sess the efficiency of intramuscular botulinum toxin type
A (BTXA) injections in a case of masseter muscle pain
in patients with temporomandibular joint dysfunction
and tension-type headache.
Methods
This is a prospective outcome study which consisted
of 42 subjects of both genders, aged 19–48 years
(mean age was 30) with masseter muscle pain related
to temporomandibular joint dysfunction and tension-type
headache. Patients were recruited from the Department of
Dental Prosthetics at the Jagiellonian University in Krakow
during the years 2009–2014 and were included in the
study if they met the following criteria: (1) presence of
TMJD which include unilateral or bilateral disc displace-
ment with or without reduction, arthralgia, degenerative
joint disease, subluxation, (2) masseter muscle pain, (3) in-
creased masticatory muscles tension, (4) TTH, (5) absence
of previous neurological treatment due to headache and a
head injury within 6 years and (6) patient consent to be in-
volved in the study. The rest of patients were excluded be-
cause of general (known hypersensitivity to BTXA,
myasthenia gravis, Eaton-Lambert syndrome, pregnancy
or lactation and taking aminoglycosides or curare-like
compounds) and/or local (infection at the proposed site of
injection) contraindications for intramuscular botulinum
toxin type A injections as well as absence of consent to be
involved in the study.
Clinical assessment of temporomandibular joints and
masticatory muscles was performed by one experienced
and self-trained examiner according to the RDC/TMD
recommendations [27, 28]. Further diagnostics was
based on survey and clinical examination according to
the International Headache Society guidelines performed
by experienced physician in the Department of Neur-
ology at the Jagiellonian University in Krakow [29]. Ac-
cording to the performed examination there was no
indications for neuroimaging examination due to the
headache in the study group. The study protocol has
been approved by the Bioethical Committee of the
Jagiellonian University in Krakow No: KBET/96/B/2007.
The data collected during the survey have been im-
portant for the purpose of the study: localization of the
headache, pain duration, and factors responsible for pain
origin. The patients were also asked whether the pain
was constant, episodic, recurrent, referred, and whether
it was felt as dull, sharp, burning or stinging. It was im-
portant whether the patient reported that the pain was
squeezing the head as well as previous treatment due to
the headache. Authors paid close attention to symptoms
that accompanied pain, such as: sleep disorders, chronic
fatigue, noise hypersensitivity, and pain referral within
the face or other areas of the head. An important aspect
was the necessity for analgesic drug administration.
After patient enrollment the treatment of masseter
muscle pain consisted of intramuscular injection of 21 U
(mice units) of type A botulinum toxin (Botox, Allergan),
in the area of the greatest cross-section surface of both
masseter bellies.
Clinical algesimetry, e.g. the evaluation of pain intensity
with the use of various scales is not devoid of subjective
influence. However, it is the currently indicated method of
measuring pain intensity at following appointments. For
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the purpose of the study two scales were applied by the
authors: VAS (Visual Analogue Scale) and VNRS (Verbal
Numerical Rating Scale). VAS is a psychometric response
scale which can be used in questionnaires [30]. It is a
measurement instrument for characteristics or attitudes
that cannot be directly measured. Participants specify their
level of pain intensity to a statement by indicating a
position along a continuous line between two end-points
(0–10). VNRS comprises assessment that is based on a
numerical 10–point scale (0–10) in combination with a
color-coded scale in which the increase in the score is ac-
companied by the increase in color intensity indicated on
the scale. Mean intensity of pain was evaluated by subjects
1 week before the injection (examination I) and 24 weeks
after the injection because of potential absence of BTXA
activity (examination II).
The results were analyzed using the Wilcoxon matched
pairs test, with statistical significance at p ≤ 0,005. The
software used in the statistical analysis was STATISTICA
version 8 (StatSoft Inc., Tulsa, Oklahoma, USA).
Results
The most frequently reported complaints included:
spontaneous masseter muscle pain and/or temporoman-
dibular joint pain, clicking in the temporomandibular
joint during mandible movements, impaired mastication
and tension-type headaches in the anterior temporal re-
gion, medial temporal region and/or occipital region.
The pain was dull, squeezing, or crushing, rarely encirc-
ling the head, and it lasted for minimum four hours daily
and had been present for at least 4 months. It was un-
pleasant for the patients but it did not interfere with
their everyday quality of life. Medication- and injury-
induced migraine headache was excluded.
Table 1 presents the clinical parameters of reported
headaches which have been diagnosed in the study
group during examination I and II such as characteris-
tics of pain, pain duration, accompanying symptoms of
pain, referral of pain and applied analgesic drugs. The
collected data have shown the valid decrease in the
number of each parameter. The headache intensity
which have been assessed using VAS & VNRS are pre-
sented in Fig. 1. The statistical analysis is presented in
Table 2 and showed a significant decrease of reported
VAS & VNRS values in examination II (p = 0,00000).
It is important that mean value of headache intensity
during examination I was 4,86 points (maximal value 8),
while the result of examination II was only 1,21
(maximal value 4). The difference between them was sta-
tistically significant because p = 0,000. The comparison
of the examination I and II data have shown a positive
changes in tension–type headache intensity. The differ-
ences mostly included: a decrease in the number of sub-
jects with bilateral pain in the temporal region and
lower number of referred pain episodes, as well as a re-
duction in the amount of analgesic drugs intake.
Discussion
Independently from the results of various studies, the rela-
tionship between tension-type headaches and temporoman-
dibular joint dysfunction can be confirmed by the decrease
in headache intensity observed after the management of
temporomandibular joint dysfunction. It is apparent par-
ticularly in cases in which no significant improvement in
the patient’s well-being is observed after conventional
neurological treatment or in which a quick recurrence of
the symptoms occurs if temporomandibular joint dysfunc-
tion treatment is not initiated [5, 9, 10, 13, 17].
The aim of the population-based cross-sectional study
conducted by Goncalves et al. was to determine the co-
existence of TTH and TMJD in adult patients [31]. The
results of their study indicate that such coexistence is
observed frequently and that those two entities should
be discussed together. The use of intramuscular BTXA
injections within the masseter muscle led to positive al-
terations in pain intensity and the nature of complaints
related with tension-type headache. Botox is, however,
routinely deposited for neurological purposes within the
temporal, occipital, and quadriceps muscles [28, 32–37].
The decrease in reported the headache following
pharmacotherapy of temporomandibular joint dysfunc-
tion suggests that tension-type headaches are in many
cases related to excessive and long-lasting tension within
the muscles of the temporomandibular joint, which re-
mains closely interrelated within the head and neck.
After the injections, the character of tension-type head-
ache changed and its intensity decreased. Moreover, a
decrease in the daily number of hours and monthly
number of days during which tension-type headache af-
fected the patient, was observed [34, 37–40].
Numerous authors in contemporary literature under-
line the role played by stress in the development of
TTH. At the same time, for several years authors of vari-
ous studies concerning etiological factors of TMJD have
been underlining that stress is an increasingly important
etiological factor in its development [41]. Also, the re-
sults of studies by Yancey et al., which showed that psy-
chorelaxation treatment and behavioral techniques were
effective in treating this pathology, indicate that psycho-
genic factors play an important role in the development
of tension-type headaches [42].
Jackson et al. have shown in the meta-analysis con-
cerning the use of BTXA in the prophylaxis of migraine
and tension-type headaches that the discussed drug had
a positive effect in both disorders [36]. According to
them, however, one should pay attention to the possibil-
ity of complications related with the application method
of the drug. Singh and Sahota stressed that Botox plays
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a key role in the treatment of chronic headaches, inde-
pendently from essential education concerning hygiene
and lifestyle modification [43].
The results of in vivo and in vitro research performed
by Ashkenazi and Blumenfeld have shown that botulinum
toxin type A is effective in reducing tension-type headache
intensity [44]. The study has shown that this drug is ef-
fective, safe, and well tolerated in the treatment of head-
ache. The drug is administered every 12 weeks, which is
convenient for some patients when compared with taking
analgesic drugs every day [45]. Mathew et al. underlined
that botulinum toxin may be a good solution for the
patients in whom oral medications (nonsteroidal anti-
inflammatory drugs, local anesthetics and gabapentin)
have not been effective [46]. A 5-year observation of 1347
patients treated due to chronic headache using 100 mice
units (MU) of botulinum toxin performed by Farinelli et
al. has showed that the drug is effective and well tolerated
by the patients. Absence of positive treatment outcomes
were observed in only 1.6 % of the patients [47]. The study
of Christidis et al. showed that other injection therapy is
effective in muscle-related headaches e.g. repeated
intramuscular tender-point injections with the serotonin
type 3 antagonist granisetron are useful in myofascial
temporomandibular disorders management [48]. It’s
mean that in close future physicians will be able to
choose treatment option from many of injection ther-
apies concerning temporomandibular disorders-related
muscle pain.
Taking into account a positive results of the BTXA in-
jections applied in the study, it should be noted that the
dose of 21 U and used operative technique are sufficient
to decrease the masseter muscle pain in patients with
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Fig. 1 The values of VAS & VNRS reported in examination I and II
Table 2 The results of statistical analysis concerning reported
values of VAS & VNRS
Examination I Examination II
Average ± SD 4,86 ± 1,84 1,21 ± 1,12
Median 5 1
Min - Max 2–8 0–4
Wilcoxon matched pairs test p = 0,00000
Table 1 The number of reported pain parameters collected in examination I and II
Tension-type headache Examination I Examination II
1. Characteristics of pain Spontaneous headache Unilateral 13 7
Bilateral 29 20
Provoked headache Unilateral 8 3
Bilateral 13 9
Dull 13 5
Squeezing 9 4
Crushing 10 3
Encircling 6 1
Throbbing 4 2
2. Pain duration Daily/h 4–6 2–3
Weekly/days 5 3
3. Accompanying symptoms of pain Sleep disorders 19 5
Chronic fatigue 28 4
Noise hypersensitivity 5 1
Appetite loss 6 1
4. Referral of pain Within the face 16 5
Within the head 9 1
5. Applied analgesic drugs Non-steroidal anti-inflammatory drugs 18 2
Paracetamol 8 1
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temporomandibular joint dysfunction and tension-type
headache. However we don’t know what happens after
6 months observations. We can assume that with the
passage of time the effect of the neurotoxin goes away
and the patient will begin to feel the pain again. We are
able to repeat whole procedure in a case of recurrence.
We have to know that current studies proofed that
BTXA injections cause mandible bone loss and uncon-
trolled structural changes in affected and unaffected
muscles [49, 50]. Therefore we have to emphasized that
BTXA injections should be taken under consideration as
a treatment of choice but not primary option in mas-
seter muscle pain management and the dose should be
kept as small as possible.
Conclusion
The intramuscular botulinum toxin type A injections
have been an efficient method of treatment in a case of
masseter muscle pain in patients with temporomandibu-
lar joint dysfunction and tension-type headache. The au-
thors recommend this therapy as a method of choice in
a masseter muscle pain management.
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